Source reputation
Moderna
1 claim in the Claimer corpus cite this source. Signals are computed from source quality, attribution accuracy, veracity assessment, and evidence depth.
85signal score
90%avg attribution
70%avg veracity
Claims1
Evidence entries2
Primary/direct sources1
Domainstechnology
Source quality mix
1 primary
Claim history
Claims citing Moderna
Moderna's mRNA cancer vaccine showed a 44% reduction in melanoma recurrence in Phase 2b trial
Moderna and Merck reported that their personalized mRNA cancer vaccine mRNA-4157/V940 (now called INTerCePT) combined with Keytruda showed a 44% reduction in risk of recurrence or death in patients with high-risk melanoma in an updated Phase 2b clinical trial.
90% attribution70% veracity2 evidence